DXCM Dexcom

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
• • New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
• • Strategic shift: Expanded market beyond insulin-using diabetics to prediabetes and broader metabolic health with OTC Stelo product
• • Quantitative metric: G7 15 Day system FDA cleared with 15.5-day wear, 8.0% MARD accuracy, coverage by Medicare and Medicaid in majority of U.S. states
• • Noteworthy fact: Dexcom ONE+ CGM system received CE Mark approval Nov 2023 and launched in multiple European countries, expanding international presence

Management Discussion & Analysis

• • Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
• • Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
• • Best segment: U.S. distributor revenue $3,195.7M up $371.3M; worst segment: U.S. direct revenue $139.2M up $73.8M (smallest absolute growth)
• • Net income $836.3M up 45% YoY with net margin 17.9% vs 14.3%
• • Cash from operations supporting R&D ($599.1M), SG&A ($1,291M), no specific buybacks/dividends noted; expectations of adequate liquidity, possible future debt market access for inorganic growth

Risk Factors

• • Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
• • Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
• • Key-person dependency on cybersecurity officers with 15-25 years experience and multiple professional certifications managing risk
• • Supply chain vulnerability linked to global IT infrastructure managed by CIO with 30 years experience in IT and supply chain
• • No specific regulatory, geopolitical, competitive, or financial risk detailed in this section

What are the latest DXCM SEC filings in 2026?

Dexcom (DXCM) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DXCM file its most recent 10-K annual report?

Dexcom (DXCM) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DXCM 10-Q quarterly reports?

Dexcom (DXCM)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every DXCM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DXCM filed recently?

Dexcom (DXCM)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DXCM insider trading activity (Form 4)?

SignalX aggregates every DXCM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DXCM file with the SEC?

Dexcom (DXCM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DXCM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Dexcom (DXCM).

What is DXCM's SEC CIK number?

Dexcom (DXCM)'s SEC CIK (Central Index Key) number is 1093557. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1093557 to look up all DXCM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DXCM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Dexcom (DXCM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.